- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00762359
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In Japan, low-dose aspirin is one of the commonly prescribed drugs for inhibiting thrombosis and thrombus formation after angina, myocardial infarction, ischemic cerebrovascular disease, coronary artery by-pass surgery and percutaneous transluminal coronary angioplasty in patients. While low-dose aspirin is effective in these cases, its use sometimes causes gastric and duodenal ulcers which can lead to gastrointestinal bleeding, and in worse cases may lead to death.
The purpose of this study is to assess the efficacy of lansoprazole versus gefarnate in patients with a history of gastric or duodenal ulcers receiving daily low dose aspirin therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Chiba
-
Matsudo-shi, Chiba, Japan
-
Yotsukaido-shi, Chiba, Japan
-
-
Ehime
-
Imabari-shi, Ehime, Japan
-
Matsuyama-shi, Ehime, Japan
-
-
Fukui
-
Fukui-shi, Fukui, Japan
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan
-
Onga-gun, Fukuoka, Japan
-
-
Gifu
-
Gifu-shi, Gifu, Japan
-
-
Gunma
-
Fujioka-shi, Gunma, Japan
-
Maebashi-shi, Gunma, Japan
-
-
Hiroshima
-
Higashihiroshima-shi, Hiroshima, Japan
-
Hiroshima-shi, Hiroshima, Japan
-
Kure-shi, Hiroshima, Japan
-
-
Hokkaido
-
Asahikawa-shi, Hokkaido, Japan
-
Hakodate-shi, Hokkaido, Japan
-
Sapporo-shi, Hokkaido, Japan
-
-
Hyogo
-
Nishinomiya-shi, Hyogo, Japan
-
-
Ibaraki
-
Higashiibaraki-gun, Ibaraki, Japan
-
Hitachinaka-shi, Ibaraki, Japan
-
Inashiki-gun, Ibaraki, Japan
-
Namegata-shi, Ibaraki, Japan
-
Tsuchiura-shi, Ibaraki, Japan
-
Yuuki-shi, Ibaraki, Japan
-
-
Ishikawa
-
Hakusan-shi, Ishikawa, Japan
-
Kanazawa-shi, Ishikawa, Japan
-
Komatsu-shi, Ishikawa, Japan
-
-
Kagawa
-
Takamatsu-shi, Kagawa, Japan
-
-
Kanagawa
-
Fujisawa-shi, Kanagawa, Japan
-
Kawasaki-shi, Kanagawa, Japan
-
Yamato-shi, Kanagawa, Japan
-
Yokohama-shi, Kanagawa, Japan
-
Yokosuka-shi, Kanagawa, Japan
-
-
Kochi
-
Kochi-shi, Kochi, Japan
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan
-
-
Mie
-
Matsusaka-shi, Mie, Japan
-
Shima-shi, Mie, Japan
-
Tsu-shi, Mie, Japan
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan
-
-
Miyazaki
-
Ebino-shi, Miyazaki, Japan
-
Miyazaki-shi, Miyazaki, Japan
-
-
Niigata
-
Joetsu-shi, Niigata, Japan
-
Niigata-shi, Niigata, Japan
-
-
Ooita
-
Beppu-shi, Ooita, Japan
-
Ooita-shi, Ooita, Japan
-
-
Osaka
-
Ibaraki-shi, Osaka, Japan
-
Matsubara-shi, Osaka, Japan
-
Osaka-shi, Osaka, Japan
-
Takatsuki-shi, Osaka, Japan
-
-
Saitama
-
Hanyuu-shi, Saitama, Japan
-
-
Shiga
-
Ootsu-shi, Shiga, Japan
-
-
Shimane
-
Hamada-shi, Shimane, Japan
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan
-
-
Tochigi
-
Shimotsuke-shi, Tochigi, Japan
-
-
Tokyo
-
Chiyoda-ku, Tokyo, Japan
-
Chuuo-ku, Tokyo, Japan
-
Hachioji-shi, Tokyo, Japan
-
Kiyose-shi, Tokyo, Japan
-
Minato-ku, Tokyo, Japan
-
Shinagawa-ku, Tokyo, Japan
-
Shinjuku-ku, Tokyo, Japan
-
Toshima-ku, Tokyo, Japan
-
-
Yamagata
-
Higashitagawa-gun, Yamagata, Japan
-
-
Yamaguchi
-
Iwakuni-shi, Yamaguchi, Japan
-
Shimonoseki-shi, Yamaguchi, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient was on low-dose aspirin treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.
- The patient was confirmed to have a history of gastric ulcer or duodenal ulcer.
Exclusion Criteria:
- Endoscopically confirmed gastric and/or duodenal ulcers on Day 1.
- Endoscopically confirmed active upper gastrointestinal hemorrhage on Day 1.
- Current or past history of aspirin-induced asthma or hypersensitivity to nonsteroidal anti-inflammatory drugs.
- Past or planned surgery affecting gastric acid secretion.
- Clinically significant hepatic or renal disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lansoprazole 15 mg QD
|
Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
Other Names:
|
ACTIVE_COMPARATOR: Gefarnate 50 mg BID
|
Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Gastric Ulcer and/or Duodenal Ulcer
Time Frame: 18 Months
|
The number of participants that developed gastric ulcer and/or duodenal ulcer at month 18 or final visit.
Ulcers are defined as mucosal defect with white coating 3 mm or greater.
|
18 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)
Time Frame: Baseline and Month 3.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach).
Erosions are mucosal defect < 3 mm.
Ulcers are mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of gastric mucosal injury.
|
Baseline and Month 3.
|
Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)
Time Frame: Baseline and Month 6.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach).
Erosions are mucosal defect < 3 mm.
Ulcers are mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of gastric mucosal injury.
|
Baseline and Month 6.
|
Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)
Time Frame: Baseline and Month 12.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach).
Erosions are mucosal defect < 3 mm.
Ulcers are mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of gastric mucosal injury.
|
Baseline and Month 12.
|
Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)
Time Frame: Baseline and Month 18.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach).
Erosions are mucosal defect < 3 mm.
Ulcers are mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of gastric mucosal injury.
|
Baseline and Month 18.
|
Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)
Time Frame: Baseline and Month 3.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions).
Erosions are defined as mucosal defect < 3 mm.
Ulcers are defined as mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of duodenal mucosal injury.
|
Baseline and Month 3.
|
Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)
Time Frame: Baseline and Month 6.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions).
Erosions are defined as mucosal defect < 3 mm.
Ulcers are defined as mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of duodenal mucosal injury.
|
Baseline and Month 6.
|
Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)
Time Frame: Baseline and Month 12.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions).
Erosions are defined as mucosal defect < 3 mm.
Ulcers are defined as mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of duodenal mucosal injury.
|
Baseline and Month 12.
|
Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)
Time Frame: Baseline and Month 18.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions).
Erosions are defined as mucosal defect < 3 mm.
Ulcers are defined as mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of duodenal mucosal injury.
|
Baseline and Month 18.
|
Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)
Time Frame: Baseline and Month 9.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and <1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves >6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach).
Erosions are mucosal defect < 3 mm.
Ulcers are mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of gastric mucosal injury.
|
Baseline and Month 9.
|
Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)
Time Frame: Baseline and Month 9.
|
The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and < 1 lesion; 2= 2 to 5 lesions ; 3= > 6 lesions).
Erosions are defined as mucosal defect < 3 mm.
Ulcers are defined as mucosal defect with white coating ≥ 3 mm.
Higher scores indicate greater severity of duodenal mucosal injury.
|
Baseline and Month 9.
|
Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)
Time Frame: 18 Months
|
Number of participants with gastric or duodenal ulcer or gastric or duodenal hemorrhagic lesion (upper gastrointestinal hemorrhage) from baseline through month 18 or final visit.
Ulcers are defined as mucosal defect with white coating 3 mm or greater.
|
18 Months
|
Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 3)
Time Frame: Baseline and Month 3.
|
Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 3.
|
Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 6)
Time Frame: Baseline and Month 6.
|
Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 6.
|
Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 9)
Time Frame: Baseline and Month 9.
|
Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 9.
|
Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 12)
Time Frame: Baseline and Month 12.
|
Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 12.
|
Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 18)
Time Frame: Baseline and Month 18.
|
Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe).
Higher scores indicate greater severity of gastrointestinal symptom.
|
Baseline and Month 18.
|
Number of Participants With Adverse Events
Time Frame: 18 Months
|
Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug.
A TEAE may also be a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.
Please see Other Adverse Events table below for TEAE listings.
|
18 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Ulcer
- Stomach Ulcer
- Duodenal Ulcer
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Dexlansoprazole
- Lansoprazole
- Gefarnate
Other Study ID Numbers
- AG-1749-CCT-351
- 070494 (REGISTRY: JapicCTI)
- U1111-1113-9929 (REGISTRY: WHO)
- R100125 (REGISTRY: JapicCTI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duodenal Ulcer
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
TakedaCompleted
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
GlaxoSmithKlinePiramal Clinical Research (Hyderabad, India)Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
The Third Xiangya Hospital of Central South UniversityLivzon Pharmaceutical Group Inc.; Yung Shin Pharm. Ind. Co., Ltd.CompletedDuodenal Ulcer Due to Helicobacter PyloriChina
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
B.P. Koirala Institute of Health SciencesCompletedPerforated Duodenal UlcerNepal
Clinical Trials on Lansoprazole
-
Charles Mel Wilcox, MDTakeda Pharmaceuticals North America, Inc.CompletedZollinger-Ellison Syndrome | Multiple Endocrine Neoplasia
-
Vanderbilt UniversityTAP Pharmaceutical Products Inc.Completed
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingPeptic UlcerKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.UnknownHealed Erosive EsophagitisKorea, Republic of
-
Emory UniversityUnknown
-
Il-Yang Pharm. Co., Ltd.Not yet recruitingPeptic UlcerKorea, Republic of
-
First Affiliated Hospital of Zhejiang UniversityBeijing Xuze Medical Technology Co., LTD.CompletedSafety Issues | Effect of DrugsChina
-
Onconic Therapeutics Inc.Not yet recruiting
-
Jordan Collaborating Cardiology GroupUniversity of JordanCompleted
-
University of UtahTerminated